About: N-acetylcysteine reduces oxidative stress in sickle cell patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: N-acetylcysteine reduces oxidative stress in sickle cell patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	N-acetylcysteine reduces oxidative stress in sickle cell patients
Creator	Hematol, Ann Biemond, Bart Duits, Ashley Brandjes, D Muskiet, Frits Nur, Erfan Otten, Hans-Martin Schnog, John-John Teerlink, Tom Nur, E Biemond, B Brandjes, P Dees, & Duits, A Elferink, R Evers, L Evers, M Ludo, & Otten, H.-M Oude, Ronald Schnog, J.-J Teerlink, T Ten Cate, H Ten, Hugo
topic	covid:634dea1a97e943d13c96553d471d5c8875f27357#this
Source	PMC
abstract	Oxidative stress is of importance in the pathophysiology of sickle cell disease (SCD). In this open label randomized pilot study the effects of oral N-acetylcysteine (NAC) on phosphatidylserine (PS) expression as marker of cellular oxidative damage (primary end point), and markers of hemolysis, coagulation and endothelial activation and NAC tolerability (secondary end points) were studied. Eleven consecutive patients (ten homozygous [HbSS] sickle cell patients, one HbSβ(0)-thalassemia patient) were randomly assigned to treatment with either 1,200 or 2,400 mg NAC daily during 6 weeks. The data indicate an increment in whole blood glutathione levels and a decrease in erythrocyte outer membrane phosphatidylserine exposure, plasma levels of advanced glycation end-products (AGEs) and cell-free hemoglobin after 6 weeks of NAC treatment in both dose groups. One patient did not tolerate the 2,400 mg dose and continued with the 1,200 mg dose. During the study period, none of the patients experienced painful crises or other significant SCD or NAC related complications. These data indicate that N-acetylcysteine treatment of sickle cell patients may reduce SCD related oxidative stress.
has issue date	2012-02-10(xsd:dateTime)
bibo:doi	10.1007/s00277-011-1404-z
bibo:pmid	22318468
has license	no-cc
sha1sum (hex)	634dea1a97e943d13c96553d471d5c8875f27357
schema:url	https://doi.org/10.1007/s00277-011-1404-z
resource representing a document's title	N-acetylcysteine reduces oxidative stress in sickle cell patients
has PubMed Central identifier	PMC3368118
has PubMed identifier	22318468
schema:publication	Ann Hematol
resource representing a document's body	covid:634dea1a97e943d13c96553d471d5c8875f27357#body_text
is http://vocab.deri.ie/void#inDataset of	https://covidontheweb.inria.fr:4443/about/id/http/ns.inria.fr/covid19/634dea1a97e943d13c96553d471d5c8875f27357
is schema:about of	named entity 'tolerability' named entity 'levels' named entity 'points' named entity 'The Red' named entity 'PAINFUL' named entity 'PATHOPHYSIOLOGY' named entity 'DOSE' named entity 'EITHER' named entity 'pilot study' named entity 'NAC' named entity 'blood' named entity 'effects' named entity 'data' named entity 'NAC' named entity 'Eleven' named entity 'patients' named entity 'plasma' named entity 'plasma levels' named entity 'endothelial activation' named entity 'SCD' named entity 'SCD' named entity 'SCD' named entity 'hemolysis' named entity 'phosphatidylserine' named entity 'N-acetylcysteine' named entity 'Oxidative stress' named entity 'sickle cell disease' named entity 'sickle cell' named entity 'HbS' named entity 'oxidative stress' named entity 'lysine' named entity 'hemoglobin' named entity 'leukocytes' named entity 'sickle cell' named entity 'von Willebrand Factor' named entity 'plasma levels' named entity 'bilirubin' named entity 'disulfide' named entity 'tolerability' named entity 'free hemoglobin' named entity 'SCD' named entity 'antioxidant' named entity 'erythrocytes' named entity 'erythrocyte' named entity 'anticoagulated' named entity 'reversed-phase HPLC' named entity 'incubation period' named entity 'free hemoglobin' named entity 'glutathione' named entity 'duodenal ulcers' named entity 'inflammatory response' named entity 'detoxifies' named entity 'CML' named entity 'erythrocytes' named entity 'pro-inflammatory cytokines' named entity 'fluorescence detection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software